Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

tradersunion353 Jun. 2 at 8:15 PM

$ABCL Overhyped junkie back to where it was What are these cllowns cheerleading and celebrating for? yeah yeah you married to ABCL have been adding and loading for over 5 years.. I get that

0 · Reply

Stocktradesmoon Jun. 2 at 7:52 PM

$ABCL

1 · Reply

DeMampCamp Jun. 2 at 7:49 PM

$ABCL You know what that looks like to me? I hate to say this, but looks like a freakin gap fill, what's the odds that it went right up to where the gap was this morning? Very strange

0 · Reply

Themk Jun. 2 at 7:47 PM

$ABCL who would have thought on that shity quarter we would be in the six dollar range wonder where we will land when price pulls back would realy like to never see the fours again.

0 · Reply

Stocktradesmoon Jun. 2 at 6:59 PM

$ABCL

0 · Reply

tradersunion353 Jun. 2 at 6:08 PM

$ABCL As this crashes cheerleading clowns with adding and loading will be all over.

1 · Reply

tradersunion353 Jun. 2 at 6:06 PM

$ABCL Overhyped junk will be back to 3 dollars THis POS never benefits shareholders.

0 · Reply

Stocktradesmoon Jun. 2 at 5:26 PM

$ABCL Rumor is that Peter Thiel is buying $ABCL on the open market

0 · Reply

Stocktradesmoon Jun. 2 at 5:19 PM

$ABCL That’s a 1 million share buy tranche! Gulp

0 · Reply

Stocktradesmoon Jun. 2 at 5:03 PM

$ABCL shhh🤔🤫 Don't tell anyone where that huge volume candle came from a couple of minutes ago. $ABCL 👀

0 · Reply

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 21 days ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 5:00 PM EDT - 22 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 22 days ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 22 days ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 22 days ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 22 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 26 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 4 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 weeks ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 6 weeks ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 6 weeks ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 7 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 3 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 4 months ago

AbCellera Biologics Slides: Corporate presentation

2026-01-12T14:36:23.000Z - 5 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 5 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 6 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 7 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 7 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 9 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 10 months ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

tradersunion353 Jun. 2 at 8:15 PM

$ABCL Overhyped junkie back to where it was What are these cllowns cheerleading and celebrating for? yeah yeah you married to ABCL have been adding and loading for over 5 years.. I get that

0 · Reply

Stocktradesmoon Jun. 2 at 7:52 PM

$ABCL

1 · Reply

DeMampCamp Jun. 2 at 7:49 PM

$ABCL You know what that looks like to me? I hate to say this, but looks like a freakin gap fill, what's the odds that it went right up to where the gap was this morning? Very strange

0 · Reply

Themk Jun. 2 at 7:47 PM

$ABCL who would have thought on that shity quarter we would be in the six dollar range wonder where we will land when price pulls back would realy like to never see the fours again.

0 · Reply

Stocktradesmoon Jun. 2 at 6:59 PM

$ABCL

0 · Reply

tradersunion353 Jun. 2 at 6:08 PM

$ABCL As this crashes cheerleading clowns with adding and loading will be all over.

1 · Reply

tradersunion353 Jun. 2 at 6:06 PM

$ABCL Overhyped junk will be back to 3 dollars THis POS never benefits shareholders.

0 · Reply

Stocktradesmoon Jun. 2 at 5:26 PM

$ABCL Rumor is that Peter Thiel is buying $ABCL on the open market

0 · Reply

Stocktradesmoon Jun. 2 at 5:19 PM

$ABCL That’s a 1 million share buy tranche! Gulp

0 · Reply

Stocktradesmoon Jun. 2 at 5:03 PM

$ABCL shhh🤔🤫 Don't tell anyone where that huge volume candle came from a couple of minutes ago. $ABCL 👀

0 · Reply

Stocktradesmoon Jun. 2 at 5:01 PM

$ABCL The new non bs bureaucratic FDA in the making is the biggest catalyst for biotech in decades. $ABCL

0 · Reply

superdupersocks Jun. 2 at 5:01 PM

$ABCL what was that!!??? 🤯

1 · Reply

Biobanker Jun. 2 at 3:56 PM

$ABCL ABCL635 related post. I understand from Carl's remarks that their criteria for ABCL635 success in the Ph2 is similar efficacy to Veozah (approved small mol targeting NK3R) but without the liver safety issues and subsequent requirement for liver safety monitoring that Veozah has. Which I understand to a degree. However, what about Elinzanetant (approved NK1R/NK3R small mol) which has good efficacy and no liver safety issues. Surely that means that ABCL635 needs to have a very clean safety profile and better efficacy than Fezo/Elinzanetant to be differentiated? Which is a pretty high bar imo. Btw I see the monthly injection of ABCL635 vs daily oral pill of Fezo/Elinzan not a major differentiator. Lmk your thoughts!

3 · Reply

sogenerous Jun. 2 at 3:15 PM

$XBI bios down on $ABVX $RMVD messes $LLY $PRME $ABCL

0 · Reply

Buying_Low_Selling_High Jun. 2 at 3:04 PM

$ABCL Im glad both Bears and Bull can be happy at the same time

0 · Reply

tradersunion353 Jun. 2 at 2:28 PM

$ABCL 9 out of 10 folks here are married to this POS overhyped underperforming stock Real investors want to make money not just park the money for a decade expect 100% returns.. clowns

0 · Reply

tradersunion353 Jun. 2 at 2:26 PM

$ABCL Clowns aka Demamp will come out like maggots and start cheerleading with Adding and loading Overhyped junkie cannot even hold its gainss Should be trading at $8 by now

0 · Reply

Stocktradesmoon Jun. 2 at 2:24 PM

$ABCL $ABCL is the best asymmetric opportunity in the market. It has a platform that can product multiple multi-billion opportunity drugs. NVIDIA of Biotech

0 · Reply

DeMampCamp Jun. 2 at 2:08 PM

$ABCL We needed this shake out, get the imposters out of here! People coming out of nowhere comparing ABCL to Palantir, etc! I'm happy where we are, I'm excited for the future, but the ridiculous comparisons have to stop. Cheers everyone!

0 · Reply

Buying_Low_Selling_High Jun. 2 at 2:06 PM

$ABCL What an opportunity for shorts to cover. Although some might see this a as weakness and short it even more ... I just wish short interest grows more and more ... Upside will be unstoppable.

1 · Reply

Stocktradesmoon Jun. 2 at 2:05 PM

$ABCL Rock bottom prices. Just buy and hold, don't worry about $.40 or $.70 price movements at these levels. These will mean nothing when this pops to its real value of around $50 $ABCL

0 · Reply

Stocktradesmoon Jun. 2 at 1:59 PM

$ABCL you know what to do no sellers with size this is a retail generational wealth phenomenon front run all the funds position yourself as a future biotech landlord volatity is the friend of the degenerate it's what gives up life itself $ABCL is a 0 to 1 company

0 · Reply

Market Cap	1.88B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	8,004,524
Avg Vol	6,431,942
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	97%
Beta	1.02
Analysts	Strong Sell
Price Target	$10.43